Macromolecular osteolytic factor synthesised by squamous carcinoma cell lines from the head and neck in vitro is interleukin 1. by Meghji, S. et al.
Br. J. Cancer (1988), 58, 17-21
The Macmillan Press Ltd.,
Macromolecular osteolytic factor synthesised by squamous carcinoma
cell lines from the head and neck in vitro is interleukin 1
S. Meghjil, J.R. Sandy', A.M. Scutt', W. Harvey', R.L. Carter 2 & M. Harris1
'Joint Department of Oral and Maxillofacial Surgery, Institute of Dental Surgery and University College, 256 Grays Inn
Road, London WCIX 8LD and 2Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK.
Summary Three human cell lines derived from oro-pharyngeal squamous cell carcinomas of the head
were investigated for bone-resorbing activity in vitro. Culture media from all three spontaneously produced
a non-dialysable osteolytic factor with activity in three in vitro assays for interleukin 1 (ILl), viz. the
lymphocyte activating factor (LAF) assay, stimulation of collagenase synthesis by articular chondrocytes,
and stimulation of prostaglandin E2 synthesis by fibroblasts. Addition of anti-human ILl antibody to the
culture media abolished all the bone-resorbing activity. Fractionation of the cell culture media by high
performance liquid chromatography (HPLC) showed a single peak of activity in the chondrocyte assay
with an apparent mol.wt of 15-17,000. This co-eluted with activity in a preparation of ILl from rat
peritoneal macrophage cultures. These results indicate that ILI is responsible for the prostaglandin-
independent bone resorbing activity synthesised by these cells in vitro, and may contribute to the bone
destruction associated with the tumour.
Bone resorption is a common feature of malignancy and can
occur as a consequence of malignant cell growth in or
adjacent to bone, or at sites distant from the malignant cells.
The localised bone destruction frequently accompanying
squamous cell carcinomas of the head and neck appears to
be a two-stage process: the first phase characterised by
osteoclastic resorption - presumably stimulated by tumour
cell products, and a second phase of resorption by tumour
cells themselves (Carter, 1985).
Since the demonstration of soluble bone resorbing activity
produced by mouse fibrosarcoma in vitro (Goldhaber, 1960),
tissue culture has been an important tool for investigating
the mechanisms of tumour-induced bone resorption. Prosta-
glandins (PG), notably PGE2, have been considered prime
candidates as local mediators of osteolysis since they are
potent stimulators of oesteoclastic bone resorption (Klein &
Raisz, 1970) and are synthesised in increased amounts by
several tumours in animals, including fibrosarcoma in mice
(Tashjian et al., 1972) the VX2 carcinoma in rabbits (Voelkel
et al., 1975), and in man, including carcinoma of the breast
(Bennett et al., 1975); Dowsett et al., 1976), and squamous
carcinomas of the head and neck (Tsao et al., 1981). PGs,
however, are only one class of bone resorbing factor which
may contribute to tumour osteolysis. Tsao et al. (1981, 1983)
showed that the bone resorption induced in culture by
explants of squamous cell carcinoma of the head and neck
was only partially inhibited by indomethacin. Indeed, carci-
noma cell lines cultured from these tumours produced bone
resorbing activity in the culture supernatants, but no detec-
table PGs. This indicated that the PGs synthesised by
tumour explants may have originated from other cell types
in the tumour, such as stromal fibroblasts.
Another group of arachidonic acid metabolites, the lipoxy-
genase products, have also been shown to possess bone
resorbing activity (Meghji et al., 1987). Porteder et al. (1984)
demonstrated that tissue from oral squamous cell carcinoma
sythesised equal amounts of cyclo-oxygenase prostaglandins
and lipoxygenase products.
Several macromolecular bone resorbing factors have been
identified recently, including tumour transforming growth
factors (TGF) (Ibbotson et al., 1983), interleukin 1 (ILI)
(Gowen et al., 1983) and tumour necrosis factor (TNF)
(Bertolini et al., 1986). It has become clear that ILl and
TNF account for much of the bone resorbing activity
attributed to 'osteoclast activating factor' (OAF) produced
by mononuclear leukocytes (Horton et al., 1972) and mye-
loma cells (Mundy et al., 1974). In view of the potent bone
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resorbing activity of ILl and the fact that it is a normal
product of keratinocytes (Luger et al., 1981), we investigated
whether it contributed to the non-prostaglandin bone resorb-
ing activity synthesised by squamous carcinoma cells in vitro.
Materials and Methods
Tumour cells
The three cell lines used were derived from squamous
carcinomas of the head and neck associated with localised
bone destruction, at the Institute of Cancer Research. The
cell lines were established as described by Tsao et al. (1981).
Two of the squamous carcinoma cell lines (HNI1 and 15)
were derived from the floor of the mouth and the third
(HN12) from the hypopharynx. For preparation of super-
natant containing bone resorbing activity the cells were
grown to confluence in Eagles minimal essential medium
(MEM; Gibco) and 10% foetal calf serum (FCS; Gibco) in
75cm2 polystyrene culture flasks, supplemented with penicil-
lin, streptomycin and kanomycin (100Uml-1 each), buffered
with sodium bicarbonate 2.25gl-1) in a humidified atmos-
phere of 95% air and 5% CO2. The cells were subcultured
weekly with 0.25% trypsin (Gibco). When the cells were
confluent the medium was then replaced with serum-free
MEM and incubated for a further 3 days. The medium was
centrifuged at lOOg to remove any debris and 1 ml aliquots
were removed for prostaglandin analysis. The remainder of
the medium was stored at -20°C. Supematants were con-
centrated 20 fold under pressure using Sartorius membrane
filters (No. Sm 145 29-025n) with a nominal molecular
weight retention of 5,000. Fractionation of cell products was
performed by HPLC gel permeation chromatography on a
Spectra Physics with a Protein Pak 125 column (Waters,
USA). The column was equilibrated with 0.15M NaCl,
0.025M acetic acid (pH 4) and calibrated with the following
markers: bovine serum albumin (66kD), egg albumin
(45kD), chymotrypsinogen (24.5kD), lactoglobulin
(18.4kD), lysozyme (14.3kD), cytochrome C (12.4kD) and
aprotinin (6.5kD). Fractions of 250 I were collected into
sterile plastic tubes, diluted 1:40 with MEM and assayed for
stimulation of collagenase synthesis in chondrocyte cultures
(see below).
Mononuclear cell supernatants
Mononuclear cell factor (MCF) was obtained from cultures
of adherent rat peritoneal macrophages (106 ml-1) stimu-
lated with concanavalin A (10ngml-1) for 3 days. The
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culture medium was dialysed against fresh medium and
stored at -70°C.
Bone resorption
Bone resorption was assayed by the measurement of calcium
released from 5-day old mouse calvaria in vitro (Zanelli et
al., 1969). Halved calvaria were cultured singly on stainless
steel grids in 30mm dishes (5 per group), with 1.5ml BGJ
medium (Flow Laboratories, Scotland), supplemented with
5% complement-inactivated rabbit serum and 50 gml-1
ascorbic acid. After 24h the media were changed, and
dialysed tumour cell medium or MCF was introduced at a
dilution of 1:5 to 1:40. MCF (1:10) and PGE2 (10-6M)
were used as positive controls. In some of the experiments
polyclonal antibody for human ILl (Genzyme, Suffolk, UK)
was added to the tumour cell line media and MCF and
incubated overnight at 40C before testing for bone resorbing
activity. The cultures were incubated for a further 48h and
the calcium content of the media was measured by auto-
mated colorimetric analysis (Gitelman, 1967). In order to
ascertain the potency of the tumour cell media recombinant
human ILl beta was tested on the bone resorbing system in
parallel.
Thymocyte proliferation assay
Interleukin 1-like activity was measured by its capacity to
enhance the mitogen-stimulated proliferation of mouse thy-
mocytes (the 'lymphocyte activation factor' (LAF) assay,
Gery et al., 1972). Briefly, thymocytes from 7-week old C3H-
HeJ mice (Harlan Olac, Blackthorn, UK) were plated in 96
well culture plates (Sterilin) at 1.5 x106 per well in 100jl
RPMI 1640 containing 5% complement-inactivated FCS,
4mM 2-mercaptoethanol, and 0.5pgml-1 concanavalin A.
The cells were cultured for 48h and 3H-thymidine (Amer-
sham International), 0.5pCi per well, was added for the last
6h. Incorporation of 3H-thymidine into 5% trichloroacetic
acid-insoluble material was measured by scintillation
counting.
Chondrocyte collagenase assay
Rabbit articular chondrocytes were prepared by a method
adapted from Evequoz et al. (1984). Slices of articular
cartilage from the knee and shoulder joints of 2-week old
New Zealand white rabbits were sequentially digested with
0.5% hylaluronidase (Sigma) for 20min at 37°C, followed by
0.25% trypsin and 0.1% bacterial collagenase (Sigma) for 1 h
at 37°C in serum free MEM, then 0.1% bacterial collagenase
for 2h in the presence of 10% FCS.
The cells obtained were washed twice and grown to
confluence in MEM with 10% FCS. Cell suspensions from
the cultures were prepared by trypsin digestion (0.25%), and
inoculated into 16mm wells in 24-well culture plates at
200,000 cells per well. The culture medium was removed
when the cells were confluent, and 0.5ml aliquots test
preparations diluted in MEM incubated in triplicate wells for
48h.
The supernatants were assayed for collagenase activity
using thermally reconstituted 3H-acetylated rat skin collagen
fibrils (Cawston & Barrett, 1979). Latent collagenase in
triplicate 50 jl samples of the supernatants was activated
with 20MI of 10mM 4-amino phenyl mercuric acetate (Sigma)
and incubated with collagen fibrils (10,000dpm/tube) for 5h
at 37°C. Collagenase activity was calculated from the release
of radioactivity into the solution, and expressed as Uml
where 1 U digests 1 jg of collagen per minute.
Tumour necrosis factor assay
The bioassay for TNF activity is based on cytotoxicity to the
murine connective tissue cell line L929 (Flick & Gifford,
1984). Cytotoxicity was measured by the quantitative uptake
of methylene blue stain by the cells after fixation (Currie,
1981).
L929 cells were seeded into 96-well microtitre plates
(Sterilin) at 4 x 104 cells per well. After overnight attach-
ment, the medium was removed and replaced with fresh
serum-free MEM containing actinomycin D (1 jgml-1) and
serial dilutions of the standard human recombinant TNF
alpha (Genzyme, Suffolk, UK) and tumour cell media at
dilution from 1:1 to 1:256 in MEM. After a 24h incubation
the medium was discarded and the cells were fixed with 5%
normal formal-saline and stained with methylene blue. The
stain was eluted into 100Ml 0.1 MHCI, and the absorbance
was measured at 650nm on an automated multi-channel
spectrophotometer (Titertek Multiscan, Flow Laboratories,
Scotland).
Stimulation offibroblast PGE2 synthesis
Fibroblast cultures were established from normal gingival
tissue obtained during routine oral surgery, and grown to
confluence in MEM with 10% FCS. The medium was
changed twice weekly, until primary cultures were estab-
lished. The fibroblasts were subcultured weekly by trypsin-
isation (0.25%), and used between the 4th and 8th passage.
Fibroblasts were seeded in 16mm culture wells (Sterilin) at
50,000 cells per well. The test preparations were diluted in
MEM and 0.5ml aliquots incubated with the cells for 48h.
PGE2 in the culture media was measured by radioimmuno-
assay: 3H-PGE2 was obtained from Amersham International;
PGE2 antiserum from Steranti and PGE2 standards from
Sigma.
Results
Bone resorption
The supernatants from all three cell lines caused significant
bone resorption, comparable with that produced by MCF.
This was partially inhibited by the addition of indomethacin
(Figure la).
The concentration-dependence of resorbing activity in the
tumour cell media is shown in Figure lb and of recombinant
ILl in Figure lc.
Addition of anti-ILl to the tumour cell line media and
MCF completely inhibited their osteolytic activity (Figure
Id).
Thymocyte proliferation
The tumour cell culture media enhanced the proliferation of
Con A-induced mouse thymocytes, indicating the production
of IL-1 like activity (Figure 2). The stimulation produced
was similar to that obtained by the preparation of MCF.
Chondrocyte collagenase production
All three cell lines stimulated collagenase production by
rabbit articular chondrocytes in culture (Figure 3). None of
the tumour cell-conditioned media had collagenase activity.
L929 cytotoxicity assay for TNF
The concentration of TNF that gave 50% maximal cell
killing (1U) was equivalent to 150pgml-1 of recombinant
human TNF alpha. There was no detectable TNF activity in
any of the tumour cell culture media in any of the concen-
tration tested (results not shown).
Fibroblast PGE2 synthesis
All three tumour cell media contained negligible PGE2
(<0.1 ngml -1), but enhanced PGE2 synthesis on addition to
fibroblasts. The stimulation was comparable to that obtained
with the MCF preparation (Figure 4).
HPLC
The HPLC fractions were assayed for ILl activity in chon-
drocyte collagenase assay. The results (Figure 5) showed a
single major peak of stimulator activity which co-eluted with
that in the MCF preparation at an Mr of 15-17,000.MACROMOLECULAR OSTEOLYTIC FACTOR 19
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Figure 2 The effects of cell supernatant (diluted 1:10) on the
LAF assay. MCF (diluted 1:10) was used as a positive control.
The results are shown as mean +s.d. (n=5). *P<0.001.
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Figure 3 The effects of cell supernatant (diluted 1:10) on the
production of collagenase by chondrocytes. MCF (diluted 1:10)
was used as a positive control. The results are shown as mean
±s.d. (n=5). *P<0.001.
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Figure 1 (a) The effects of cell supernatant (diluted 1:10) (with
and without indomethacin (10-6M) on bone resorption. Crossed
hatched bars show the effect of indomethacin. Mononuclear cell
factor (MCF) and PGE2 (10-6 M) were used as positive controls.
The results are shown as mean +s.d. (n=5 bones per group);
* =P<0.001 compared with the control group. (b) The effects of
conditioned media from the cell lines (diluted 1:40, 1:20, 1:10
and 1:5) PGE2 (10-6M) was used as positive control. The
results are shown as mean +s.d. (n =5 bones per group);
*P<0.05 compared with the control group. HN1I1 - HN12
-0-; HN15 -*-. (c) The effect human recombinant tLl at the
following concentrations; 0.01, 0.1, 1 and lOnM on bone resorp-
tion. PGE2 (10-6M) was used as positive control. The results
are shown as mean +s.d. (n=5 bones per group); *P<0.05
compared with the control group. (d) The effects of tumour cell
culture media and MCF (diluted 1:10) on bone resorption and
the effect of the same media in the presence of anti-human ILl
on bone resorption (crossed hatched bars) PGE2 (10-6M) was
used as positive control. The results are shown as mean +s.d.
(n=5 bones per group); *=P<0.001 compared with the control
group. The bone resorbing activity of MCF and the three cell
lines was abolished by the addition of anti-human ILl.
20
E 01
C
0- 10
r
*
Control MCF HN-1 1 HN-12 HN-15
Figure 4 The effects of cell supernatant (diluted 1:10) on PGE2
production by fibroblasts. MCF (diluted 1:10) was used as a
positive control. The results are shown as mean + s.d. (n =5).
*P<0.001.
Discussion
These results have demonstrated that squamous carcinoma
cell lines synthesise an osteolytic factor in vitro with the
characteristics of the cytokine ILl. These, and similar cell
lines which have previously been validated in terms of their
karyotypes, ultrastructure and growth as xenografts, are
known to synthesise osteolytic activity which was not
attributable to prostaglandin E2, and was largely unaffected
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by the inclusion of indomethacin in the cultures (Tsao et al.,
1983).
We have shown that the osteolytic factor is non-dialysable
(i.e. has a mol. wt in excess of - 10,000) and that the culture
medium from the cell lines also contains a non-dialysable
factor which has co-mitogenic activity in the thymocyte
proliferation (LAF) assay (Figure 2), stimulates collagenase
synthesis by articular chondrocytes (Figure 3) and stimulates
PGE2 synthesis in fibroblast cultures (Figure 4). The LAF
assay and the stimulation of chondrocyte collagenase syn-
thesis are the bioassays normally used to detect ILI. The
LAF assay will also detect IL2 (Gery et al., 1972), but the
stimulation of chondrocyte collagenase synthesis is indepen-
dent of IL2 (Evequoz et al., 1984), thus indicating ILI
activity in the cell culture media.
We have also demonstrated that there is no TNF activity
in the supernatants. Studies with the polyclonal antibody for
ILI showed that the bone resorbing activity of the super-
natant was completely blocked, indicating most of the osteo-
lytic activity in the cell supernatants was ILI-like.
Furthermore the stimulation of fibroblast PGE2 synthesis
also suggests cytokine activity in the supernatants. This
activity in macrophage cultures, first reported by Dayer et
al. (1977), was later shown to be due to ILI (Mizel et al.,
1981). More evidence for the identity of the osteolytic factor
as ILI was provided by the inhibitory effect of adding anti-
human ILI (Figure Id).
Fractionation of the culture media by HPLC (Figure 5)
showed that the stimulatory activity in the chondrocyte
collagenase assay co-eluted with MCF at an Mr of 15-
17,000. This is also consistent with its identity as ILI
(Dinarello et al., 1977).
Recently another cytokine, TNF, has also been shown to
share several characteristicsof ILI (reviewed by Le & Vilcek,
1987) including the stimulation of bone resorption in vitro
(Bertolini et al., 1986). As the mol. wt of TNF (17,000) is
similar to that of ILI it is possible that TNF contributed to
the stimulation of bone resorption and PGE2 synthesis by
fibroblasts. However, no TNF-like activity was detectable in
the tumour cell media over a wide range of dilutions.
Furthermore TNF does not exhibit activity in the LAF assay
(Dinarello et al., 1985) and does not stimulate metalloprotei-
nase synthesis by chondrocytes (Schnyder et al., 1987). TNF
does not, therefore appear to contribute to the osteolytic
activity synthesised by the tumour cell in vitro.
Another family of peptides, tumour-derived transforming
growth factors (TGF), have recently been shown to stimulate
bone resorption (Tashjian et al., 1985; Ibbotson et al., 1986)
and are thought to be potential mediators of tumour-induced
osteolysis. However, TGF does not show ILl-like activity in
the LAF and chondrocyte collagenase assays, and is there-
fore unlikely to contribute to the activity which co-elutes
with ILl on HPLC.
The initial stages of tumour-induced bone destruction are
mediated by osteoclastic activity, whereas the later stages can
involve direct invasion and destruction of the bone by
tumour cells alone (Galasko & Bennett, 1976; Carter, 1985).
There is much evidence that prostaglandins are synthesised
by human carcinomas (Bennett et al., 1975; Dowsett et al.,
1976; Tsao et al., 1981, 1983) and, in view of their potent
bone resorbing activity, notably PGE2 (Klein & Raisz,
1970), they have been considered prime candidates as osteo-
lytic mediators. The experiments reported by Tsao et al.
(1983) showed that although explanted tumour fragments
synthesised amounts of PGE2 enough to account for the
majority of bone resorption in vitro, the carcinoma cell lines
synthesised little prostaglandins but significant prostaglandin-
independent osteolytic factors. The experiments reported
here show that ILl may account for this PG-independent
osteolytic activity.
Although ILl is an extremely potent resorbing peptide and
may contribute to osteolysis by the tumour tissue, its ability
to stimulate prostaglandin synthesis in connective tissue cells
may be of equal or greater importance. Fibroblasts are
target cells for ILl action and respond by synthesising
prostaglandins - notably PGE2 (Dayer et al., 1977; Mizel et
al., 1981), PGF2 and prostacyclin (Harvey et al., 1984). In
the squamous cell carcinoma, therefore, secretion of ILl by
the carcinoma cells is likely to stimulate prostaglandin
synthesis by the infiltrating stromal cells such as fibroblasts
and capillary endothelial cells.
We propose, therefore that ILl secretion by the carcinoma
cells can cause bone resorption by two mechanisms: stimula-
tion of osteoclast activity, probably mediated by osteoblasts
(Thomson et al., 1986), and indirectly by the stimulation of
prostaglandin synthesis in stromal cells infiltrating or sur-
rounding the tumour.
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